{"id":21386,"date":"2025-01-13T20:15:29","date_gmt":"2025-01-13T12:15:29","guid":{"rendered":"https:\/\/flcube.com\/?p=21386"},"modified":"2025-01-13T20:15:30","modified_gmt":"2025-01-13T12:15:30","slug":"menarini-group-expands-oncology-pipeline-with-insilico-medicine-license","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=21386","title":{"rendered":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License"},"content":{"rendered":"\n

Italy\u2019s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal with China-based AI drug discovery firm Insilico Medicine. The agreement grants Menarini global development and commercialization rights to a preclinical small molecule targeting oncology indications. This strategic move further expands Menarini’s oncology pipeline, leveraging Insilico’s advanced AI-driven drug discovery capabilities.<\/p>\n\n\n\n

Small Molecule Inhibitor and Development<\/strong>
The small molecule inhibitor, developed under Insilico’s generative chemistry engine Chemistry42 and by Insilico’s drug discovery team, targets a broad range of solid tumor cancers. It has demonstrated broad anti-tumor activity in selected cancers during preclinical development, positioning it as a promising candidate for the treatment of various solid tumor cancers.<\/p>\n\n\n\n

Agreement Terms and Financials<\/strong>
Under the terms of the agreement, Stemline will pay Insilico an upfront payment of USD 20 million, out of a total of USD 550 million, which includes all development, regulatory, and commercial milestone payments, alongside tiered royalties. This significant financial commitment reflects the potential of the preclinical asset and the confidence in Insilico’s drug discovery platform.<\/p>\n\n\n\n

Previous Collaboration<\/strong>
Menarini first partnered with Insilico in January of last year for an exclusive license deal focused on a KAT6A inhibitor developed on Insilico\u2019s platform. The latest deal further strengthens the collaboration between the two companies, combining Menarini’s global reach with Insilico’s innovative AI-driven drug discovery approach.<\/p>\n\n\n\n

Future Prospects<\/strong>
The licensing deal between Menarini Group and Insilico Medicine highlights the growing importance of AI in drug discovery and development. By obtaining rights to this preclinical small molecule, Menarini is well-positioned to advance its oncology portfolio and bring novel treatments to patients with solid tumor cancers. This partnership underscores the potential of AI to accelerate the development of innovative therapeutics in the fight against cancer.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

Italy\u2019s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal…<\/p>\n","protected":false},"author":1,"featured_media":21387,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[16,1047,1723],"class_list":["post-21386","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-cancer","tag-menarini","tag-stemline-therapeutics"],"yoast_head":"\nMenarini Group Expands Oncology Pipeline with Insilico Medicine License - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Italy\u2019s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal with China-based AI drug discovery firm Insilico Medicine. The agreement grants Menarini global development and commercialization rights to a preclinical small molecule targeting oncology indications. This strategic move further expands Menarini's oncology pipeline, leveraging Insilico's advanced AI-driven drug discovery capabilities.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=21386\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Menarini Group Expands Oncology Pipeline with Insilico Medicine License\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=21386\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-01-13T12:15:29+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-13T12:15:30+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"675\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Menarini Group Expands Oncology Pipeline with Insilico Medicine License\",\"datePublished\":\"2025-01-13T12:15:29+00:00\",\"dateModified\":\"2025-01-13T12:15:30+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386\"},\"wordCount\":307,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1313.png\",\"keywords\":[\"Cancer\",\"Menarini\",\"Stemline Therapeutics\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21386#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=21386\",\"name\":\"Menarini Group Expands Oncology Pipeline with Insilico Medicine License - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1313.png\",\"datePublished\":\"2025-01-13T12:15:29+00:00\",\"dateModified\":\"2025-01-13T12:15:30+00:00\",\"description\":\"Italy\u2019s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal with China-based AI drug discovery firm Insilico Medicine. The agreement grants Menarini global development and commercialization rights to a preclinical small molecule targeting oncology indications. This strategic move further expands Menarini's oncology pipeline, leveraging Insilico's advanced AI-driven drug discovery capabilities.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=21386\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1313.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/1313.png\",\"width\":1080,\"height\":675,\"caption\":\"Menarini Group Expands Oncology Pipeline with Insilico Medicine License\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=21386#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Menarini Group Expands Oncology Pipeline with Insilico Medicine License\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License - Insight, China's Pharmaceutical Industry","description":"Italy\u2019s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal with China-based AI drug discovery firm Insilico Medicine. The agreement grants Menarini global development and commercialization rights to a preclinical small molecule targeting oncology indications. This strategic move further expands Menarini's oncology pipeline, leveraging Insilico's advanced AI-driven drug discovery capabilities.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=21386","og_locale":"en_US","og_type":"article","og_title":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=21386","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-01-13T12:15:29+00:00","article_modified_time":"2025-01-13T12:15:30+00:00","og_image":[{"width":1080,"height":675,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=21386#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=21386"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License","datePublished":"2025-01-13T12:15:29+00:00","dateModified":"2025-01-13T12:15:30+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=21386"},"wordCount":307,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=21386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png","keywords":["Cancer","Menarini","Stemline Therapeutics"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=21386#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=21386","url":"https:\/\/flcube.com\/?p=21386","name":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=21386#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=21386#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png","datePublished":"2025-01-13T12:15:29+00:00","dateModified":"2025-01-13T12:15:30+00:00","description":"Italy\u2019s Menarini Group, through its subsidiary Stemline Therapeutics Inc., has entered into a licensing deal with China-based AI drug discovery firm Insilico Medicine. The agreement grants Menarini global development and commercialization rights to a preclinical small molecule targeting oncology indications. This strategic move further expands Menarini's oncology pipeline, leveraging Insilico's advanced AI-driven drug discovery capabilities.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=21386#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=21386"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=21386#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png","width":1080,"height":675,"caption":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=21386#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Menarini Group Expands Oncology Pipeline with Insilico Medicine License"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/01\/1313.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21386","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=21386"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21386\/revisions"}],"predecessor-version":[{"id":21388,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/21386\/revisions\/21388"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/21387"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=21386"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=21386"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=21386"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}